Novartis: Neuroendocrine Tumors trials

The registry lists 18 Neuroendocrine Tumors studies with Novartis as lead sponsor. 0 are open to participants now and 10 have results posted.

Phase 1 2Phase 2 5Phase 3 2Phase 4 4No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) PatientsCompletedNCT04524442Phase 4Results posted
• Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.CompletedNCT01789281Phase 4Results posted
• Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine TumorsTerminatedNCT01628913Phase 2Results posted
• An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)CompletedNCT01595009Phase 4Results posted
• A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid TumoursCompletedNCT01578239Phase 3Results posted
• Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)CompletedNCT01524783Phase 3Results posted
• Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNETTerminatedNCT01374451Phase 2Results posted
• RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine DifferentiationCompletedNCT01317615Phase 4Results posted
• RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in EuropeCompletedNCT00688623Phase 2Results posted
• Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to ChemotherapyCompletedNCT00363051Phase 2Results posted
• A Study of Peptide Receptor Radionuclide Therapy (PRRT) Use in Neuroendocrine Tumor (NET) Patients in GermanyCompletedNCT07653126
• Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)CompletedNCT05816720
• Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETsCompletedNCT04727723
• Post-Authorization Long-Term Safety Study of LUTATHERAActive, not recruitingNCT03691064
• EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA TxApproved for marketingNCT02705313
• Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETsCompletedNCT01590199Phase 1
• Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)CompletedNCT01364415Phase 1
• EPO906 in Carcinoid and Other Neuroendocrine TumorsCompletedNCT00050349Phase 2